A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
| dc.contributor.author | Kei, A. A. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Tsimihodimos, V. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:39:13Z | |
| dc.date.available | 2015-11-24T19:39:13Z | |
| dc.identifier.issn | 1532-8600 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24224 | |
| dc.rights | Default Licence | - |
| dc.title | A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease | en |
| heal.abstract | The focus of this review is on the role of apolipoprotein C-II (apoC-II) in lipoprotein metabolism and the potential effects on the risk of cardiovascular disease (CVD). We searched PubMed/Scopus for articles regarding apoC-II and its role in lipoprotein metabolism and the risk of CVD. Apolipoprotein C-II is a constituent of chylomicrons, very low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein (HDL). Apolipoprotein C-II contains 3 amphipathic alpha-helices. The lipid-binding domain of apoC-II is located in the N-terminal, whereas the C-terminal helix of apoC-II is responsible for the interaction with lipoprotein lipase (LPL). At intermediate concentrations (approximately 4 mg/dL) and in normolipidemic subjects, apoC-II activates LPL. In contrast, both an excess and a deficiency of apoC-II are associated with reduced LPL activity and hypertriglyceridemia. Furthermore, excess apoC-II has been associated with increased triglyceride-rich particles and alterations in HDL particle distribution, factors that may increase the risk of CVD. However, there is not enough current evidence to clarify whether increased apoC-II causes hypertriglyceridemia or is an epiphenomenon reflecting hypertriglyceridemia. A number of pharmaceutical interventions, including statins, fibrates, ezetimibe, nicotinic acid, and orlistat, have been shown to reduce the increased apoC-II concentrations. An excess of apoC-II is associated with increased triglyceride-rich particles and alterations in HDL particle distribution. However, prospective trials are needed to assess if apoC-II is a CVD marker or a risk factor in high-risk patients. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | 10.1016/j.metabol.2011.12.002 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/22304839 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0026049511004112/1-s2.0-S0026049511004112-main.pdf?_tid=ad272f14bf8a0a8e62987c22f6670853&acdnat=1333532152_36db3edf4b5249f540090962fb72f44b | - |
| heal.journalName | Metabolism | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2012 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: